Drugs / ERY001
ERY001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02195180 | Jul 2014 → Feb 2017 | pancreatic adenocarcinoma | ERYtech Pharma | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ERY001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02195180 ↗ |
| Known as | Eryaspase | “PURPOSE: Eryaspase is composed of l-asparaginase encapsulated in erythrocytes and has demonstrated significant efficacy in a randomized phase II trial.” PMID 32605910 ↗ Jun 2020 |
| Known as | erythrocyte-encapsulated asparaginase | “This Phase IIb (NCT02195180) open-label study evaluated erythrocyte-encapsulated asparaginase (eryaspase) in combination with chemotherapy in second-line advanced pancreatic...” PMID 31760314 ↗ Nov 2019 |
| Modality | Protein / enzyme biologic | “erythrocyte-encapsulated asparaginase (eryaspase)” PMID 31760314 ↗ Nov 2019 |